explore -WSS

explore

author：leisure time 2025-09-29 12:09:38 - browse：53

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： AbbVie dramatically boosts its spending on lobbying

knowledge

WSS

What to know about Saharan dust affecting the US and how it can affect health

What to know about Saharan dust affecting the US and how it can affect health

FDA official pushes for dedicated emerging pathogens team

Beach reads and more: STAT's 2023 summer book list

A new study sees potential in DNA sequencing of infants

Elizabeth Holmes on track for early release from her 11

Wikipedia

explore

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

California’s proposed $25 per hour health care minimum wage

DIEP, the 'gold standard' of breast reconstruction, is under threat

Why ADHD is under

Wildfire smoke exposes gaps in outdoor worker protections

7 of the most gruesome medical devices in history

Tori Bowie and the unacceptable rates of Black maternal death

Review: 'Barbie' will hit you like a shot in the heart

Cancer drug shortages should be causing more outrage

Artificial intelligence advances fuel industry trying to preserve loved ones after death

entertainment

Threats against the LGBTQIA+ community intensifying: Department of Homeland Security

Iowa House, Senate pass 6

AbbVie dramatically boosts its spending on lobbying

A double vaccine crisis is endangering millions of children

Iowa House, Senate pass 6

Study: Pain burden is higher in Black NFL players than white ones

focus

knowledge

knowledge

Wikipedia